Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Net Income towards Common Stockholders: 2022-2024

Historic Net Income towards Common Stockholders for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.6 million.

  • Entrada Therapeutics' Net Income towards Common Stockholders fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • Per Entrada Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $65.6 million for FY2024, which was up 1,087.80% from -$6.6 million recorded in FY2023.
  • Entrada Therapeutics' 5-year Net Income towards Common Stockholders high stood at $65.6 million for FY2024, and its period low was -$94.6 million during FY2022.
  • For the 3-year period, Entrada Therapeutics' Net Income towards Common Stockholders averaged around -$11.9 million, with its median value being -$6.6 million (2023).
  • Data for Entrada Therapeutics' Net Income towards Common Stockholders shows a peak YoY soared of 1,087.80% (in 2024) over the last 5 years.
  • Over the past 3 years, Entrada Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$94.6 million in 2022, then skyrocketed by 92.98% to -$6.6 million in 2023, then soared by 1,087.80% to $65.6 million in 2024.